When.com Web Search

  1. Ads

    related to: vascepa over the counter

Search results

  1. Results From The WOW.Com Content Network
  2. How Much Does Vascepa Cost on Medicare? - AOL

    www.aol.com/much-does-vascepa-cost-medicare...

    How much will you pay for Vascepa under Medicare? According to Optum Perks, 30 capsules of Vascepa can cost between $91 and $99 without insurance, depending on the pharmacy you get them from.

  3. Ethyl eicosapentaenoic acid - Wikipedia

    en.wikipedia.org/wiki/Ethyl_eicosapentaenoic_acid

    Ethyl eicosapentaenoic acid (E-EPA, icosapent ethyl), sold under the brand name Vascepa among others, is a medication used to treat dyslipidemia [4] and hypertriglyceridemia. [3] It is used in combination with changes in diet in adults with hypertriglyceridemia ≥ 150 mg/dL.

  4. What does Vacepsa cost on Medicare? - AOL

    www.aol.com/lifestyle/does-vacepsa-cost-medicare...

    How much will someone pay for Vascepa on Medicare? According to Optum Perks, 30 capsules of Vascepa cost as little as $91.84, depending on the pharmacy. The generic version — icosapent ethyl ...

  5. Omega-3-acid ethyl esters - Wikipedia

    en.wikipedia.org/wiki/Omega-3-acid_ethyl_esters

    Omega-3-acid ethyl esters are used in addition to changes in diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. [3] In the European Union and other major markets outside the US, omega-3-acid ethyl esters are indicated for hypertriglyceridemia by itself, or in combination with a statin for people with mixed dyslipidemia.

  6. Over-the-counter drug - Wikipedia

    en.wikipedia.org/wiki/Over-the-counter_drug

    Over-the-counter (OTC) medicines at FamilyDoctor.org, maintained by the American Academy of Family Physicians. Contains extensive information on over-the-counter drugs and their responsible use, including specific guidance on several drug classes in question-and-answer format and information on common drug interactions.

  7. Investigators to Present New REDUCE-IT Subanalysis of VASCEPA ...

    lite.aol.com/tech/story/0022/20241111/9270771.htm

    DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association’s Scientific ...